93P Pseudoprogression in immunotherapy: Illusion or reality? P-PIT study

Immune Checkpoint inhibitors (ICI) have emerged as one of the leading cancer therapies. ICI enhance patient's immune response against tumor cells and promote tumor T-cell infiltration. As a result, inflammatory mechanism can lead to increased tumor lesions that could be wrongly misinterpreted as progressive disease. Currently, there are no imaging modalities that can differentiate true progression from pseudoprogression (PP). Although the iRECIST criteria have been developed to characterize these atypia, they appear to be inadequate in practice.